Research programme: GSG2 protein/CDK8 inhibitors - Selvita

Drug Profile

Research programme: GSG2 protein/CDK8 inhibitors - Selvita

Alternative Names: SEL 120; SEL120-34; SEL120-34A

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Selvita
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase 8 inhibitors; GSG2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Colorectal cancer

Most Recent Events

  • 15 Nov 2016 Pharmacodynamics and pharmacokinetics data from a Preclinical trial in Cancer presented at the 28th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Poland (PO)
  • 11 Nov 2014 Preclinical trials in Colorectal cancer in Poland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top